Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Critical Outcome Technologies (COTI) has received US patent for its oncology drug candidate, COTI-2, by United States Patent and Trademark Office (USPTO).
Subscribe to our email newsletter
The compound has been discovered by the company’s Artificial Intelligence drug discovery process, CHEMSAS.
The specific cellular targeting, low toxicity, and efficacy of the drug candidate help in treatment of cancers that over express Akt/Akt2.
COTI CEO Wayne Danter said the US patent provides validation of CHEMSAS, and its ability to discover novel small molecules.
"This patent provides protection for COTI-2 until 2030 and is a valuable asset to us in the advancement of our licensing initiatives," Danter added.